XML 47 R37.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Segment Reporting [Abstract] |
Sales from Products | Sales of the Company’s products were as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
($ in millions) | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total
Pharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Keytruda | $ | 3,795 |  |  | $ | 2,543 |  |  | $ | 6,338 |  |  | $ | 3,331 |  |  | $ | 2,095 |  |  | $ | 5,426 |  |  | $ | 11,142 |  |  | $ | 7,261 |  |  | $ | 18,403 |  |  | $ | 9,307 |  |  | $ | 6,180 |  |  | $ | 15,487 |
Alliance revenue-Lynparza (1) | 153 |  |  | 146 |  |  | 299 |  |  | 144 |  |  | 140 |  |  | 284 |  |  | 439 |  |  | 445 |  |  | 884 |  |  | 427 |  |  | 397 |  |  | 825 |
Alliance revenue-Lenvima (1) | 160 |  |  | 100 |  |  | 260 |  |  | 142 |  |  | 60 |  |  | 202 |  |  | 476 |  |  | 258 |  |  | 734 |  |  | 426 |  |  | 235 |  |  | 660 |
Welireg | 51 |  |  | 3 |  |  | 54 |  |  | 38 |  |  | — |  |  | 38 |  |  | 141 |  |  | 6 |  |  | 146 |  |  | 83 |  |  | — |  |  | 83 |
Alliance revenue-Reblozyl (2) | 43 |  |  | 10 |  |  | 52 |  |  | 32 |  |  | 7 |  |  | 39 |  |  | 108 |  |  | 33 |  |  | 142 |  |  | 87 |  |  | 37 |  |  | 124 |
Vaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gardasil/Gardasil 9 | 838 |  |  | 1,746 |  |  | 2,585 |  |  | 957 |  |  | 1,337 |  |  | 2,294 |  |  | 1,718 |  |  | 5,297 |  |  | 7,015 |  |  | 1,803 |  |  | 3,624 |  |  | 5,428 |
ProQuad/M-M-R II/Varivax | 567 |  |  | 146 |  |  | 713 |  |  | 532 |  |  | 136 |  |  | 668 |  |  | 1,435 |  |  | 388 |  |  | 1,823 |  |  | 1,337 |  |  | 379 |  |  | 1,716 |
RotaTeq | 108 |  |  | 48 |  |  | 156 |  |  | 154 |  |  | 102 |  |  | 256 |  |  | 381 |  |  | 203 |  |  | 584 |  |  | 427 |  |  | 218 |  |  | 644 |
Vaxneuvance | 182 |  |  | 33 |  |  | 214 |  |  | 15 |  |  | 1 |  |  | 16 |  |  | 423 |  |  | 65 |  |  | 488 |  |  | 31 |  |  | 1 |  |  | 32 |
Pneumovax 23 | 42 |  |  | 98 |  |  | 140 |  |  | 68 |  |  | 63 |  |  | 131 |  |  | 105 |  |  | 223 |  |  | 327 |  |  | 280 |  |  | 177 |  |  | 457 |
Vaqta | 32 |  |  | 37 |  |  | 69 |  |  | 27 |  |  | 36 |  |  | 64 |  |  | 91 |  |  | 60 |  |  | 151 |  |  | 72 |  |  | 62 |  |  | 134 |
Hospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bridion | 265 |  |  | 159 |  |  | 424 |  |  | 233 |  |  | 190 |  |  | 423 |  |  | 841 |  |  | 572 |  |  | 1,413 |  |  | 665 |  |  | 579 |  |  | 1,244 |
Prevymis | 70 |  |  | 87 |  |  | 157 |  |  | 49 |  |  | 64 |  |  | 114 |  |  | 186 |  |  | 244 |  |  | 430 |  |  | 136 |  |  | 174 |  |  | 310 |
Dificid | 69 |  |  | 5 |  |  | 74 |  |  | 72 |  |  | 6 |  |  | 77 |  |  | 199 |  |  | 16 |  |  | 215 |  |  | 184 |  |  | 12 |  |  | 196 |
Primaxin | — |  |  | 41 |  |  | 41 |  |  | — |  |  | 63 |  |  | 63 |  |  | 2 |  |  | 173 |  |  | 174 |  |  | 1 |  |  | 185 |  |  | 185 |
Noxafil | 4 |  |  | 47 |  |  | 51 |  |  | 13 |  |  | 49 |  |  | 62 |  |  | 29 |  |  | 138 |  |  | 167 |  |  | 39 |  |  | 141 |  |  | 180 |
Zerbaxa | 29 |  |  | 24 |  |  | 53 |  |  | 24 |  |  | 19 |  |  | 43 |  |  | 86 |  |  | 71 |  |  | 157 |  |  | 64 |  |  | 55 |  |  | 120 |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Alliance revenue-Adempas/Verquvo (3) | 96 |  |  | (4) |  |  | 92 |  |  | 85 |  |  | 3 |  |  | 88 |  |  | 249 |  |  | 10 |  |  | 259 |  |  | 244 |  |  | 14 |  |  | 258 |
Adempas | — |  |  | 65 |  |  | 65 |  |  | — |  |  | 57 |  |  | 57 |  |  | — |  |  | 189 |  |  | 189 |  |  | — |  |  | 181 |  |  | 181 |
Virology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lagevrio | — |  |  | 640 |  |  | 640 |  |  | — |  |  | 436 |  |  | 436 |  |  | — |  |  | 1,236 |  |  | 1,236 |  |  | 1,523 |  |  | 3,336 |  |  | 4,859 |
Isentress/Isentress HD | 58 |  |  | 61 |  |  | 119 |  |  | 68 |  |  | 93 |  |  | 161 |  |  | 165 |  |  | 212 |  |  | 377 |  |  | 196 |  |  | 270 |  |  | 466 |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Belsomra | 23 |  |  | 35 |  |  | 58 |  |  | 20 |  |  | 42 |  |  | 62 |  |  | 60 |  |  | 117 |  |  | 176 |  |  | 60 |  |  | 139 |  |  | 199 |
Immunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Simponi | — |  |  | 179 |  |  | 179 |  |  | — |  |  | 173 |  |  | 173 |  |  | — |  |  | 539 |  |  | 539 |  |  | — |  |  | 540 |  |  | 540 |
Remicade | — |  |  | 45 |  |  | 45 |  |  | — |  |  | 49 |  |  | 49 |  |  | — |  |  | 144 |  |  | 144 |  |  | — |  |  | 163 |  |  | 163 |
Diabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Januvia | 328 |  |  | 252 |  |  | 581 |  |  | 332 |  |  | 385 |  |  | 717 |  |  | 842 |  |  | 800 |  |  | 1,642 |  |  | 958 |  |  | 1,294 |  |  | 2,252 |
Janumet | 43 |  |  | 211 |  |  | 255 |  |  | 90 |  |  | 327 |  |  | 417 |  |  | 182 |  |  | 755 |  |  | 937 |  |  | 258 |  |  | 1,089 |  |  | 1,347 |
Other pharmaceutical (4) | 197 |  |  | 353 |  |  | 549 |  |  | 194 |  |  | 410 |  |  | 603 |  |  | 540 |  |  | 1,147 |  |  | 1,690 |  |  | 511 |  |  | 1,225 |  |  | 1,736 |
Total Pharmaceutical segment sales | 7,153 |  |  | 7,110 |  |  | 14,263 |  |  | 6,620 |  |  | 6,343 |  |  | 12,963 |  |  | 19,840 |  |  | 20,602 |  |  | 40,442 |  |  | 19,119 |  |  | 20,707 |  |  | 39,826 |
Animal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Livestock | 205 |  |  | 669 |  |  | 874 |  |  | 186 |  |  | 643 |  |  | 829 |  |  | 543 |  |  | 1,987 |  |  | 2,530 |  |  | 521 |  |  | 1,965 |  |  | 2,486 |
Companion Animal | 257 |  |  | 269 |  |  | 526 |  |  | 289 |  |  | 253 |  |  | 542 |  |  | 875 |  |  | 942 |  |  | 1,817 |  |  | 904 |  |  | 929 |  |  | 1,834 |
Total Animal Health segment sales | 462 |  |  | 938 |  |  | 1,400 |  |  | 475 |  |  | 896 |  |  | 1,371 |  |  | 1,418 |  |  | 2,929 |  |  | 4,347 |  |  | 1,425 |  |  | 2,894 |  |  | 4,320 |
Total segment sales | 7,615 |  |  | 8,048 |  |  | 15,663 |  |  | 7,095 |  |  | 7,239 |  |  | 14,334 |  |  | 21,258 |  |  | 23,531 |  |  | 44,789 |  |  | 20,544 |  |  | 23,601 |  |  | 44,146 |
Other (5) | 100 |  |  | 199 |  |  | 299 |  |  | 227 |  |  | 398 |  |  | 625 |  |  | 135 |  |  | 561 |  |  | 696 |  |  | 383 |  |  | 925 |  |  | 1,307 |
| $ | 7,715 |  |  | $ | 8,247 |  |  | $ | 15,962 |  |  | $ | 7,322 |  |  | $ | 7,637 |  |  | $ | 14,959 |  |  | $ | 21,393 |  |  | $ | 24,092 |  |  | $ | 45,485 |  |  | $ | 20,927 |  |  | $ | 24,526 |  |  | $ | 45,453 |
U.S. plus international may not equal total due to rounding. (1) Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3). (2) Alliance revenue for Reblozyl represents royalties and, for the first nine months of 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3). (3) Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3). (4) Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately. (5) Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $173 million and $533 million for the nine months ended September 30, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September 30, 2023 and 2022 also includes $118 million and $156 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Sales by Geographic Area | Consolidated sales by geographic area where derived are as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022
United States | $ | 7,715 |  |  | $ | 7,322 |  |  | $ | 21,393 |  |  | $ | 20,927 |
Europe, Middle East and Africa | 3,327 |  |  | 3,286 |  |  | 9,978 |  |  | 11,228 |
China | 1,694 |  |  | 1,442 |  |  | 5,322 |  |  | 3,957 |
Japan | 1,081 |  |  | 673 |  |  | 2,514 |  |  | 2,776 |
Asia Pacific (other than China and Japan) | 781 |  |  | 854 |  |  | 2,475 |  |  | 2,792 |
Latin America | 895 |  |  | 684 |  |  | 2,298 |  |  | 1,933 |
Other | 469 |  |  | 698 |  |  | 1,505 |  |  | 1,840 |
| $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 45,485 |  |  | $ | 45,453 |
Reconciliation of Segment Profits to Income before Taxes | A reconciliation of segment profits to Income Before Taxes is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022
Segment profits: |  |  |  |  |  |  |
Pharmaceutical segment | $ | 10,407 |  |  | $ | 9,590 |  |  | $ | 29,400 |  |  | $ | 28,263 |
Animal Health segment | 421 |  |  | 515 |  |  | 1,453 |  |  | 1,672 |
Total segment profits | 10,828 |  |  | 10,105 |  |  | 30,853 |  |  | 29,935 |
Other profits | 190 |  |  | 377 |  |  | 374 |  |  | 831 |
Unallocated: |  |  |  |  |  |  |
Interest income | 73 |  |  | 40 |  |  | 295 |  |  | 62 |
Interest expense | (317) |  |  | (244) |  |  | (836) |  |  | (727) |
Amortization | (562) |  |  | (460) |  |  | (1,582) |  |  | (1,623) |
Depreciation | (401) |  |  | (448) |  |  | (1,175) |  |  | (1,257) |
Research and development | (3,183) |  |  | (4,277) |  |  | (20,523) |  |  | (9,374) |
Restructuring costs | (126) |  |  | (94) |  |  | (344) |  |  | (288) |
Charge for Zetia antitrust litigation settlements | — |  |  | — |  |  | (573) |  |  | — |
Other unallocated, net | (882) |  |  | (1,416) |  |  | (2,554) |  |  | (4,628) |
| $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 |

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration